StockData
Myriad Genetics Inc logo

Myriad Genetics Inc (MYGN) stock

MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.53−0.01 (-0.18%)

Close on Nov 18, 2026Market cap $528.94MP/E –Yield –

Myriad Genetics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Myriad Genetics's pe ratio was 561.2× on Oct 31, 2019, against 24.3× a year earlier. Over the last 5 years it ranged from 12.3× to 561.2×, with a median of 25.6×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2019Oct 31, 2019561.2×+522.4
2018Dec 31, 201838.8×+14.7
2017Dec 29, 201724.0×+9.8
2016Dec 30, 201614.2×−19.5
2015Dec 31, 201533.7×+14.6
2014Dec 31, 201419.1×+9.1
2013Dec 31, 201310.0×−9.9
2012Dec 31, 201219.9×+1.7
2011Dec 30, 201118.2×+2.7
2010Dec 31, 201015.5×−14.8
2009Dec 31, 200930.3×–

More Myriad Genetics figures

See a number that looks wrong?